Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 2627 Hanover St, Palo Alto, CA 94304, USA
- Website
- intacttherapeutics.com
- Founded
- 2015
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Adepthera LLC | Palo Alto, CA | 325412 Pharmaceutical Preparation Manufacturing |
| Fzata Inc. | Halethorpe, MD | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Thetis Pharmaceuticals LLC | Deep River, CT | — |
| IHP Therapeutics Inc. | San Carlos, CA | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| Vitakey Inc. | Washington, DC | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
About the company
Intact Therapeutics is a for-profit corporation registered to receive federal grant awards since November 2017. The company specializes in developing innovative drug delivery platforms and therapeutics, with a focus on gastrointestinal applications. Intact Therapeutics' primary offerings to the federal government through grant awards involve research and development of novel treatments for conditions like upper gastrointestinal bleeding and ulcerative colitis. Their proprietary technology centers around thermogel-based drug delivery systems, which have the potential to revolutionize treatment approaches in these areas.
Through federal grant awards, Intact Therapeutics has undertaken several significant research projects. The company received a $999,783 Phase II Small Business Innovation Research (SBIR) grant from the National Science Foundation (NSF) to develop a thermogel-based drug delivery platform for upper gastrointestinal bleeding treatment. This project aims to create a product that can rapidly stop bleeding prior to endoscopic treatment, potentially reducing patient morbidity and mortality. Additionally, Intact Therapeutics was awarded a grant from the National Institute of Diabetes and Digestive and Kidney Diseases to develop a novel thermogel for topical treatment of ulcerative colitis. This project focuses on creating a formulation that combines a microbial metabolite-derived agonist with an innovative thermosensitive delivery platform to treat moderate-to-severe distal ulcerative colitis. Both of these projects demonstrate Intact Therapeutics' commitment to advancing medical treatments through the development of sophisticated drug delivery systems, supported by federal funding agencies dedicated to scientific and medical progress.
Quick answers
Is Intact Therapeutics registered in SAM.gov?
Yes. Intact Therapeutics's SAM.gov registration is active through November 5, 2027.
What is Intact Therapeutics's CAGE code?
Intact Therapeutics's CAGE code is 803L1, and its Unique Entity ID (UEI) is ZYZ1FU7HBU73.
What is Intact Therapeutics's most recent federal award?
Intact Therapeutics's most recent federal grant award is Sbir phase II: a thermogel-based drug delivery platform for the upper gastrointestinal bleeding treatment (2307164), from National Science Foundation, on May 1, 2024.
On GovTribe
See Intact Therapeutics's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors